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Actual versus recommended storage
temperatures of oral anticancer
medicines at patients’ homes
ND Vlieland1, BJF van den Bemt2,3,4, DA van Riet-Nales5,
ML Bouvy6, ACG Egberts1,6 and H Gardarsdottir1,6
Abstract
Background: Substantial quantities of unused medicines are returned by patients to the pharmacy each year.
Redispensing these medicines would reduce medicinal waste and health care costs. However, it is not known if medicines
are stored by patients as recommended in the product label. Inadequate storage may negatively affect the medicine and
reduce clinical efficacy whilst increasing the risk for side effects.
Objective: To investigate the proportion of patients storing oral anticancer medicines according to the temperature
instructions in the product label.
Methods: Consenting adult patients from six Dutch outpatient hospital pharmacies were included in this study if they
used an oral anticancer medicine during February 2014 – January 2015. Home storage temperatures were assessed by
inclusion of a temperature logger in the original cancer medicines packaging. The primary outcome was the proportion
of patients storing oral anticancer medicines as specified in the Summary of Product Characteristics, either by recalcu-
lating the observed temperature fluctuations to a single mean kinetic temperature or by following the temperature
instructions taking into account a consecutive 24-h tolerance period.
Results: Ninety (81.1%) of the 111 included patients (47.8% female, mean age 65.2 (SD: 11.1)) returned their tem-
perature loggers to the pharmacy. None of the patients stored oral anticancer medicines at a mean kinetic temperature
above 25C, one patient stored a medicine requiring storage below 25C longer than 24 h above 25C. None of the
patients using medicines requiring storage below 30C kept their medicine above 30C for a consecutive period of 24 h
or longer.
Conclusion: The majority of patients using oral anticancer medicines store their medicines according to the tempera-
ture requirements on the product label claim. Based on our results, most oral anticancer medicines will not be negatively
affected by temperature conditions at patients’ homes for a maximum of three months and are likely to be suitable for
redispensing.
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Introduction
The increased availability of anticancer medicines
allowing for oral administration to treat different
types of cancer puts a growing burden on national
health care budgets. The costs of oral anticancer medi-
cines were estimated at 173 million Euros in 2015 in the
Netherlands, which is approximately one fourth of
total expenditure on anticancer medicines.1 To make
better use of current health resources, several sugges-
tions have been made to minimize medicine waste lead-
ing to reduced costs and contributing to a sustainable
health care for patients with cancer. These include pre-
scribing smaller quantities2 and redispensing unused
medicines.3 However, for the latter, the quality of medi-
cines needs to be guaranteed and the storage conditions
at patients’ homes remain a concern. Inadequate stor-
age may negatively affect the medicine and reduce clin-
ical efficacy whilst increasing the risk for side effects.
Some oral anticancer medicines should be dispensed
in their original packaging to keep them protected from
light and moisture, and require temperature conditions
below 25C or 30C. Storage claims are defined by the
drug companies and based on standardized drug stabil-
ity test conditions that are outlined in the Q1A
International Conference on Harmonisation (ICH)
guideline for new drug products.4 Stability test condi-
tions established by the ICH for climate zone I and II
(all European countries) are based on ambient tempera-
ture and relative humidity measurements performed in
the 1980s.5,6 Stability indicating parameters include
appearance, assay (potency), impurities, water content,
dissolution, particle size and/or other parameters that
may be required by the authorities. Stability tests are
normally performed at long term, intermediate and
accelerated conditions (Table 1). At the time of submis-
sion to the regulatory authorities, medicines which fulfil
all criteria when tested at long-term and accelerated
conditions receive no special storage conditions
towards temperature. If a medicine fails to meet the
specification after six months accelerated testing,
it should be tested at intermediate conditions
(30C/65%RH) as well. When test outcomes at inter-
mediate and accelerated conditions are out of specifica-
tion, the corresponding storage claims will be to store
below 25C.7 All product label storage claims should be
described in the European Summary of Product
Characteristics (SmPC) or United States Product
Insert and correspond with the product labels inform-
ing distributors, pharmacies, and patients about the
required storage conditions.
Few studies have investigated home storage condi-
tions of medicines. Two studies suggest that medicines
are often not adequately stored at home,8,9 but the
studies did not investigate storage temperatures of
specific medicines at home over a longer period of
time or the influence of ambient temperature. In this
study, we investigate the proportion of patients storing
oral anticancer medicines according to the temperature
instruction in the product label. Furthermore, we inves-
tigate the influence of the ambient temperature on the
actual storage temperature of oral oncolytics in patient
homes.
Methods
Setting and study population
This multicenter observational study was conducted in
six outpatient pharmacies in the Netherlands between
February 2014 and January 2015. Adult patients (18
years) were eligible for inclusion if they were receiving
one of the following oral anticancer medicines: imati-
nib, gefitinib, erlotinib, sunitinib, sorafenib, dasatinib,
lapatinib, nilotinib, pazopanib, vandetanib, dabrafenib,
everolimus, axitinib, vemurafenib, abiraterone, enzalu-
tamide, and lenalidomide. Patients with obvious cogni-
tive impairments and non-Dutch-speaking patients
were excluded. Eligible patients received both written
and oral information and were asked for a written
informed consent. The study protocol was reviewed
and approved by the Medical Ethics Review Board of
the University Medical Center Utrecht (protocol refer-
ence number 14-628/C).
Study procedure
Patients received their oral anticancer medicine in the
original company’s primary (e.g. bottles, blisters) and
secondary (e.g. cardboard boxes) packaging including a
Safe-Rx temperature logger, which was attached to the
outer packaging and put in a closed polyethylene
seal bag. The Safe-Rx temperature logger is a small
Table 1. Stability studies and storage conditions for new and
existing drug products. (4,12)
Stability study Storage condition
Minimum time
period covered
by data at
submission
Long term 25C 2C/60% RH 5% RH or
30C 2C/65% RH 5% RHa
6b/12 months
Intermediate 30C 2C/65% RH 5% RH 6 months
Accelerated 40C 2C/75% RH 5% RH 6 months
RH: relative humidity.
aThe drug company decides whether long-term studies are performed at
25C 2C/60% RH 5% RH or 30C 2C/65% RH 5% RH.
bFor existing active substances and related finished products.
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(18mm 32mm 2mm) temperature measurement
device that has been validated according to inter-
national standards.10 The logger was activated upon
medicine dispense and device settings were adjusted to
have a temperature measurement every 2min. Patients
received standard instructions on adequate storage
upon dispensing by the pharmacy’s personnel.
No extra information was given to those participating
in the study. Patients were asked to keep the tempera-
ture logger and package in the seal bag and to return
the temperature logger(s) when the dispensed medicine
had been used. In case the temperature loggers were not
returned within four months, a reminder was sent by
post including a pre-stamped envelope to return the
temperature logger(s). If needed, second and third
reminders were given by telephone.
Outcomes
The primary outcome was the proportion of patients
storing oral anticancer medicines as specified in the
SmPC within the storage tolerances as specified
below. We investigated if oral anticancer medicines
were stored in accordance with the conditions specified
in the SmPC and were not exposed to a mean kinetic
temperature (MKT) above 25C (sorafenib and ever-
olimus) or above 30C (imatinib, lapatinib, nilotinib,
vandetanib and abiraterone). The MKT is described
in the ICH Q1A guideline as follows:
A single derived temperature that, if maintained over a
defined period of time, affords the same thermal chal-
lenge to a drug substance or drug product as would be
experienced over a range of both higher and lower tem-
peratures for an equivalent defined period.4
The MKT was calculated for each patient and package
over the complete storage period and is generally higher
than the mean temperature and takes into account tem-
perature variations and their influence on the medicine
based on the Arrhenius equation. Furthermore, we
investigated if medicines were stored above 25C or
30C for a consecutive period of at least 24 h.11,12
Other oral anticancer medicines (gefitinib, erlotinib,
sunitinib, dasatinib, pazopanib, dabrafenib, enzaluta-
mide, lenalidomide, vemurafenib and axitinib) do
not require special temperature storage conditions.
We investigated whether oral anticancer medicines in
this group were stored at an MKT above 40C or
temperatures that exceeded 40C for at least 24 h. The
maximum storage temperature of 40C was based on
accelerated stability test conditions medicines were
exposed to.4 Information on storage temperature
requirements were retrieved from the SmPC of each
medicine (consulted on 19 October 2015).13 We also
set the maximum storage period at three months,
which corresponds with the maximum dispensing
period in the Netherlands. Secondary outcomes were
defined as the total storage time for all patients of
oral anticancer medicines according to the product
label and the relation between storage temperatures
and ambient temperature values obtained from hourly
measurements from the Royal Netherlands
Meteorological Institute in De Bilt, the Netherlands.14
Data analysis
Demographic data were presented using descriptive
statistics. Characteristics (gender and age) of patients
lost to follow-up were compared with patient charac-
teristics of those who returned temperature loggers to
the pharmacies using t test for normally distributed
continuous variables and Pearson chi-square test for
differences in proportions. A two-sided p value less
than 0.05 was considered to indicate a significant dif-
ference. The proportion of storage time at or above
25C or at or above 30C and the proportion of
patients that stored oral anticancer medicines according
to the product label were calculated. The mean and 97.5
percentile of daily storage temperatures and mean daily
ambient temperatures were calculated and plotted in a
line chart. Hourly storage and ambient temperature
data were used to visualize individual patient data.
The effect of ambient temperatures on daily storage
temperatures was investigated in spring (1 March
2014–31 May 2014), summer (1 June 2014–31 August
2014), autumn (1 September 2014–30 November 2014)
and winter (1 December 2014–31 January 2015) and
analyzed following a linear mixed effects model.
All calculations were made with the statistical package
from SAS version 9.2.
Results
Study population
A total of 111 patients were included in the study of
which 81.1% (n¼ 90) returned their temperature
loggers to the pharmacy. ‘Temperature logger lost or
discarded’ (n¼ 3) and ‘patient deceased’ (n¼ 4) were
reasons for not returning the temperature logger to
the pharmacy. Fourteen patients did not respond
after the third reminder to return their temperature
logger and were considered lost to follow-up. Of our
study population, 47.8% (n¼ 43) was female and the
mean age was 65.2 (SD: 11.1) years (Table 2). Male
patients were more likely not to return the temperature
logger to the pharmacy (p< 0.001). Most patients
who returned the temperature loggers received imati-
nib (20.0%) followed by everolimus (13.3%) and
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nilotinib (11.1%). Thirteen patients (14.5%) used oral
anticancer medicines that required storage below 25C,
37 patients (41.1%) used products that required storage
below 30C and 40 patients (44.4%) used products that
required no special temperature conditions. The mean
total measured storage time per patient was 64.0 days
(SD: 25.3).
Primary outcome
Eighty-nine patients (98.9%) met the criteria of the pri-
mary endpoint and stored their oral anticancer medi-
cines according to the storage temperature defined in
the SmPC (Table 3). One patient stored a medicine that
requires storage below 25C for a consecutive period
longer than 24 h above 25C. None of the patients
stored their medicine at an MKT above 25C or
above 30C and most medicines were stored between
15C and 25C. None of the patients using medicines
requiring storage below 30C kept their medication
above 30C for a consecutive period of 24 h or longer.
Secondary outcomes
The proportion of measured storage time per tempera-
ture for patients using oral anticancer medicines that
require storage below 25C (Figure 1(a)), below 30C
(Figure 1(b)) and those that require no special storage
temperature conditions (Figure 1(c)) are presented in
Figure 1(a) to (c). The proportion of total storage
time below 25C (Figure 1(a)) for patients using oral
anticancer medicines that require storage below 25C
(sorafenib, everolimus) was 642.0 days (71.3%). For
patients using oral anticancer medicines that require
storage below 30C (Figure 1(b)), the proportion of
storage time below 30C was 1143.3 days (93.4%).
There was no storage time above 40C for patients
using oral anticancer medicines that required no special
temperature conditions (Figure 1(c)). Mean storage
temperatures per day based on all patient measure-
ments are presented in Figure 2 and ranged from
17.4C (SD: 0.56) on 20 February, 2014 to 25.6C
(SD: 1.59) on 20 July 2014. Mean daily storage tem-
perature in patients using oral anticancer medicines
that require storage below 25C, below 30C or no
special temperature storage conditions were 20.6C
(SD: 4.1), 20.7C (SD: 3.0) and 21.6C (SD: 3.1),
Table 2. Patient characteristics (N¼ 111).
Patients included in
analysis (N¼ 90)
Patients lost to
Follow-up
(N¼ 21)
Age (mean, SD) 65.2 (11.1) 65.1 (13.5)
Gender N % N %
Female 43 47.8 6 28.6a
Type of oral anticancer medicine
Everolimus 12 13.3 3 14.3
Sorafenib 1 1.1 1 4.8
Abiraterone 9 10.0 2 9.5
Imatinib 18 20.0 2 9.5
Nilotinib 10 11.1 0 0.0
Axitinib 0 0.0 1 4.8
Dabrafenib 1 1.1 0 0.0
Dasatinib 6 6.7 1 4.8
Enzalutamide 3 3.3 3 14.3
Erlotinib 2 2.2 0 0.0
Gefitinib 3 3.3 2 9.5
Lenalidomide 7 7.8 3 14.3
Pazopanib 4 4.4 1 4.8
Sunitinib 8 8.9 1 4.8
Vemurafenib 6 6.7 1 4.8
ap< 0.001
Table 3. Compliance to drug storage temperature criteria for oral anticancer medicines.
Sorafenib,
everolimus
(T¼ 25)
Imatinib/lapatinib/nilotinib/
vandetanib/abiraterone
(T¼ 30)
Gefitinib/erlotinib/sunitinib/
dasatinib/pazopanib/dabrafenib/
enzalutamide/lenalidomide/
vemurafenib/axitinib (T¼ 40)
Patients, n(%) 13 (14.4) 37 (41.1) 40 (44.5)
Patients with at least one
package where MKTT
0 (0.0) 0 (0.0) 0 (0.0)
Patient with at least on package
where storage temperature were
24 h or longerT
1 (7.7) 0 (0.0) 0 (0.0)
MKT: mean kinetic temperature.
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Figure 1. (a) proportion of total storage time per temperature for oral anticancer medicines requiring storage below 25C, (b)
proportion of total storage time per temperature for oral anticancer medicines requiring storage below 30C and (c) proportion of
total storage time per temperature for oral anticancer medicines requiring no special temperature conditions.
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Figure 2. Daily mean (solid line) and 97.5th percentile (dashed line) of storage temperatures from all patients versus daily mean
ambient temperatures (dotted line) from 13 March 2014 until 31 January 2015.
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respectively. Maximum and minimum storage tempera-
tures of 58.0C (21 June 2014) and 1.9C (19 January
2015) were measured. In summer months, an increase
of 1C ambient temperature resulted in an increase of
0.30C storage temperature. This effect was less in the
spring (increase of 0.20C/1C ambient temperature),
autumn (increase of 0.20C/1C ambient temperature)
and winter (increase of 0.06C/1C ambient tempera-
ture) period.
Discussion
The majority of patients using oral anticancer medi-
cines store their medicines according to temperature
conditions stated on the product label. Most oral antic-
ancer medicines are, therefore, likely to be suitable for
redispensing if returned unused to the pharmacy,
although for some oral anticancer medicines sensitive
to humidity and light, these storage conditions should
also be assessed. In the Netherlands, a relationship
between actual storage temperature at patient’ homes
and ambient temperature has been identified, which is
the most significant during summer.
Our temperature measurements are in line with what
Hewson et al.15 reported on home storage conditions in
New Zealand (climate zone I/II) which showed mean
storage temperatures from 18.4C to 23.6C with
maximum storage temperatures above 25C. Oral
anticancer medicines may be stored at temperatures
above 25C in daily practice, but it is unclear if excur-
sions up to several days above 25C will affect medicine
quality. ICH stability test requirements for authoriza-
tion of new medicines and existing active substances
and their related medicines are based on the
MKT, and were investigated by Wolfgang Grimm in
1985 and 1986.5,6 As the MKT value expresses the
cumulative thermal stress, it is assumed that tempera-
ture excursions (up to 40C) above 25C or 30C induce
no significant changes in the medicines’ chemical stabil-
ity.16 None of the medicines we investigated were stored
at MKTs above 25C, which makes it unlikely that
significant chemical degradation of the medicines
occurred in our study. For climate zone I in Europe
(the Netherlands, Amsterdam), an MKT of 19.3C
and mean temperature of the four hottest months of
20.6C were measured.6 These temperatures are slightly
lower than mean storage temperatures that we mea-
sured in our study (20.6C–21.6C). In comparison
with the Netherlands, storage conditions in patient
homes in climate zone II southern European countries
such as Greece and Italy (where mean ambient tem-
peratures in the hottest four months are over 30C)
are likely to be higher and might result in more frequent
and longer periods of storage time above 25C.5,6
Furthermore, if patients travel to countries classified
as climate zone III or IV, such as India, Israel or
Brazil, storage claims based on climate zones I/II sta-
bility tests do not longer apply. It is considered that
product stability testing in climate zone III and IV
would require at least 12 months 30C/65%RH (long-
term conditions) and 6 months 40C/75%RH (acceler-
ated conditions).17,18 Patients are often not aware of
different climate zones and might risk medicine expos-
ure to high temperatures at a specific place at home
(e.g. near the heating or window) or abroad.
According to the Public Assessment Report (PAR)
documentation, all oral anticancer medicines in our
study were tested, according to the ICH Q1A guideline
for new medicines, at 25C/60%RH or 30C/65%RH
long-term/intermediate conditions and at accelerated
conditions 40C/75%RH. The majority of oral antic-
ancer medicines in our study were stable within product
specifications at long-term and accelerated conditions.
The documentation for two oral anticancer medicines
that require storage below 25C – everolimus and
sorafenib – describe a slight increase in impurities
at accelerated test conditions.19,20 No information is
available in the PAR documentation about the possible
consequences of inadequate storage.
Unused medicines are returned to pharmacies every
day.21 The possibility of redispensing expensive unused
medicines has been discussed in the Netherlands to
reduce health care costs and the ambition to create a
more sustainable pharmaceutical supply chain.3 This
study investigated important requirements for redispen-
sing and identified medicine quality as one of the main
concerns and temperature monitoring as a critical qual-
ity parameter. The majority of patients in our study
stored oral anticancer medicines according to the stor-
age temperature on the product label. Most medicines
were stored at MKTs below 25C or 30C and without
spikes of 24 h or longer above the defined tolerances.
Only for the patients using medicines that require stor-
age below 25C, storage temperatures are often above
25C for shorter periods less than 24 h. Although the
quality of most oral anticancer medicines can be guar-
anteed by measuring storage temperatures at home,
other storage requirements, such as the ability and will-
ingness of patients keeping the medicine in the original
container to protect against moisture and light if stated
in the product label are needed to guarantee the medi-
cine quality. If implementing a redispensing system,
it should be legally possible, cost beneficial, patients
should be willing to participate and accept medicines
that have been stored, quality should be assured and
there should be clear guidelines (e.g. party responsible
for quality of redispensed medicines).3
As far as we know, this is the first study that meas-
ures home storage temperatures of oral anticancer
medicines. Although our sample size was small and
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there were only six outpatient pharmacies that recruited
patients in the study, this study suggests that a large
majority of patients store oral anticancer medicines
according to recommended storage temperatures. The
moment of medicine administration by the patient was
unknown and some patients may have started weeks later
after the dispensing date or left some of the medicines
unused. Therefore, we do not know the exact period of
time oral anticancer medicines were exposed to the tem-
peraturesmeasured.Weminimized the possible time tem-
perature loggers were not measuring temperature storage
data by having a maximum measurement period of three
months. By setting the measurement period at three
months according to the maximum prescription period,
we could have excluded actual storage time. In addition,
patients were aware of the study and might have changed
their storage practices and locations before starting the
measurement period, which might have resulted in an
overestimation of the number of patients that store medi-
cines according to the recommended storage temperature
on the product label. Ambient temperature measure-
ments were performed at one location only, whereas
patients on locations elsewhere might have been exposed
to different ambient temperatures which could have influ-
enced the relation between storage temperatures
and ambient temperatures. Our results are restricted to
climate zone I and II countries, as countries in other cli-
mate zones require other test conditions and storage con-
ditions for medicines. Finally, no measurements were
performed to assess the relative humidity or light expos-
ure at patient homes. Most oral anticancer medicines are,
according to the SmPC, not sensitive to light or moisture
and if they are, packages should protect medicines from
light exposure and moisture. However, for some oral
anticancer medicines that are sensitive to moisture and
light, these conditions should be assessed.
Conclusion
The majority of patients using oral anticancer medi-
cines store their medicines according to the temperature
conditions stated on the product label. However, if
storage below 25C is required, patients may need add-
itional advice as where to store their medicines at home
or when travelling. Before medicines would be suitable
for redispensing from a quality perspective, other cri-
teria including light and humidity should be assessed
for medicines sensitive to light or moisture. Especially,
in warmer periods, there is a correlation between ambi-
ent temperature and storage temperature. As tempera-
tures in the Netherlands rarely are above 25C, this is
not a major issue in the Netherlands. We suggest, how-
ever, that this correlation should be further investigated
for other climate zone I/II countries with higher daily
ambient temperatures.
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